Summary & Overview
HCPCS Q4176: Neopatch or Therion, per Square Centimeter
HCPCS Level II code Q4176 designates a per-square-centimeter add-on for Neopatch or Therion topical/device applications billed in addition to a primary procedure. This code captures area-based supply or device use for adjunctive skin and wound therapy and matters nationally because it affects how providers report supplemental material or device usage that adds to procedural complexity and cost. Proper use of Q4176 ensures separate recognition of the device or topical application when it augments a primary procedure.
Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find concise benchmarks and coverage notes, common billing practices for add-on, per-area items, and clinical context for when an area-based device or supply is appropriate to report. The publication outlines coding intent, typical sites of service such as outpatient clinics and wound care centers, and payer coverage considerations relevant at the national level. Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line are noted where applicable. This summary equips coding managers, billing staff, and policy analysts with a clear understanding of the code’s purpose and where to look for payer-specific coverage details.
Billing Code Overview
HCPCS Level II code Q4176 describes Neopatch or therion, billed per square centimeter as an add-on item to be reported separately in addition to a primary procedure. The service type is best characterized as topical/device application for wound or skin therapy, supplied and billed according to the surface area treated (per square centimeter).
Typical sites of service include outpatient clinics, wound care centers, physician offices, and hospital outpatient departments where adjunctive topical or device-based skin treatments are applied alongside a primary procedure.
Clinical & Coding Specifications
Clinical Context
A patient with a full-thickness skin defect after tumor excision or chronic wound debridement requires placement of a dermal regenerative matrix component such as a neopatch/therion product charged by area. Typical patients include adults undergoing Mohs micrographic surgery for skin cancer (e.g., squamous cell carcinoma) or reconstructive procedures after trauma. The clinical workflow begins with preoperative evaluation and diagnosis coding, followed by surgical excision or debridement in an ambulatory surgery center or hospital outpatient department. After achieving hemostasis and preparing the wound bed, the surgeon sizes the defect and applies the neopatch/therion product to cover the dermal defect; the product is billed per square centimeter as an add-on supply using Q4176 in addition to the primary surgical procedure. The wound is secured with appropriate dressings; postoperative instructions and follow-up visits are scheduled for assessment of graft take and healing. Typical site of service is an outpatient surgical setting, ambulatory surgery center, or hospital outpatient department.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no modifiers apply and billing requires the base code only |